Biphenyloxadiazole compounds or salts thereof, preparation method and application thereof
CN121108070BActive Publication Date: 2026-08-28XUZHOU MEDICAL UNIVERSITY
Patent Information
- Application Number
- CN202511356124.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-22
- Publication Date
- 2026-08-28
- Estimated Expiration
- 2045-09-22
AI Technical Summary
Technical Problem
提示,HDAC 与炎性疼痛发生关系密切,其抑制剂可能是较为有效的镇痛工具,但其作用的有效靶点仍需进一步研究
Benefits of technology
[0044]本发明提供的一类双苯基噁二唑类化合物或其药学上可接受的盐在用作HDAC6激酶抑制剂时,对促炎因子具有抑制作用,且在给药剂量为30 mg/kg时,对疼痛模型小鼠的抑制活性与ACY-1215与相当,为中等到重度疼痛、急性疼痛、慢性疼痛、神经痛、炎症性疼痛、伤害性疼痛、癌性疼痛、痛觉过敏以及内脏疼痛的治疗和预防提供了一类新型先导化合物。
✦ Generated by Eureka AI based on patent content.
Smart Images

Figure CN121108070B_ABST
Abstract
A kind of diphenyl oxadiazole compound or its salt, its preparation method and application, diphenyl oxadiazole compound has the structure shown in formula (I), wherein R1It is at least independently selected from hydrogen, halogen, cyano, nitro, C1-6Alkyl, C1-6Alkoxy, C3-8Cycloalkyl, aryl, heteroaryl or heterocyclic group, n is 1~7.The diphenyl oxadiazole alkane compound or its pharmaceutically acceptable salt can be used to prepare the drug for preventing and / or treating pain.Especially, the diphenyl oxadiazole compound can be targeted HDAC6 to treat pain, has inhibitory effect on proinflammatory factors, and when the administration dose is 30 mg / kg, the inhibitory activity on pain model mouse is equivalent to ACY-1215, provides a new path for the treatment and prevention of moderate to severe pain, acute pain, chronic pain, neuropathic pain, inflammatory pain, nociceptive pain, cancer pain, hyperalgesia and visceral pain.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Selective histone deacylase 8 (HDAC8) degrading agents and methods of use thereof
CN119278034A
Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of s1p1, and methods of use thereof
US20190002450A1